Rachel Vatnsdal
Stock Analyst at JP Morgan
(4.38)
# 339
Out of 4,960 analysts
65
Total ratings
58.7%
Success rate
17.27%
Average return
Main Sectors:
Stocks Rated by Rachel Vatnsdal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HSIC Henry Schein | Maintains: Overweight | $80 → $76 | $69.60 | +9.20% | 4 | Aug 7, 2025 | |
| ADPT Adaptive Biotechnologies | Maintains: Overweight | $10 → $14 | $13.00 | +7.69% | 5 | Aug 6, 2025 | |
| AVTR Avantor | Maintains: Overweight | $17 → $14 | $13.27 | +5.50% | 1 | Aug 4, 2025 | |
| CAI Caris Life Sciences | Initiates: Overweight | $31 | $39.30 | -21.12% | 1 | Jul 14, 2025 | |
| TXG 10x Genomics | Maintains: Neutral | $12 → $9 | $14.30 | -37.06% | 4 | May 9, 2025 | |
| TWST Twist Bioscience | Maintains: Underweight | $40 → $33 | $28.59 | +15.42% | 2 | May 6, 2025 | |
| RGEN Repligen | Maintains: Overweight | $200 → $190 | $124.79 | +52.26% | 6 | Apr 29, 2025 | |
| RVTY Revvity | Maintains: Neutral | $120 → $100 | $94.15 | +6.21% | 4 | Apr 29, 2025 | |
| NVST Envista Holdings | Maintains: Neutral | $20 → $19 | $21.72 | -12.52% | 4 | Mar 6, 2025 | |
| WAT Waters | Maintains: Neutral | $380 → $390 | $302.19 | +29.06% | 4 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $50 → $55 | $80.52 | -31.69% | 3 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $55 | $61.40 | -10.42% | 1 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $165 → $160 | $121.63 | +31.55% | 6 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $650 → $670 | $499.99 | +34.00% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $17 → $20 | $6.02 | +232.23% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,300 → $1,400 | $1,321.45 | +5.94% | 2 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.38 | - | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $60 → $90 | $35.54 | +153.24% | 2 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $250 → $270 | $211.80 | +27.48% | 4 | Dec 20, 2023 |
Henry Schein
Aug 7, 2025
Maintains: Overweight
Price Target: $80 → $76
Current: $69.60
Upside: +9.20%
Adaptive Biotechnologies
Aug 6, 2025
Maintains: Overweight
Price Target: $10 → $14
Current: $13.00
Upside: +7.69%
Avantor
Aug 4, 2025
Maintains: Overweight
Price Target: $17 → $14
Current: $13.27
Upside: +5.50%
Caris Life Sciences
Jul 14, 2025
Initiates: Overweight
Price Target: $31
Current: $39.30
Upside: -21.12%
10x Genomics
May 9, 2025
Maintains: Neutral
Price Target: $12 → $9
Current: $14.30
Upside: -37.06%
Twist Bioscience
May 6, 2025
Maintains: Underweight
Price Target: $40 → $33
Current: $28.59
Upside: +15.42%
Repligen
Apr 29, 2025
Maintains: Overweight
Price Target: $200 → $190
Current: $124.79
Upside: +52.26%
Revvity
Apr 29, 2025
Maintains: Neutral
Price Target: $120 → $100
Current: $94.15
Upside: +6.21%
Envista Holdings
Mar 6, 2025
Maintains: Neutral
Price Target: $20 → $19
Current: $21.72
Upside: -12.52%
Waters
Mar 6, 2025
Maintains: Neutral
Price Target: $380 → $390
Current: $302.19
Upside: +29.06%
Feb 25, 2025
Downgrades: Neutral
Price Target: $50 → $55
Current: $80.52
Upside: -31.69%
Feb 21, 2025
Maintains: Overweight
Price Target: $50 → $55
Current: $61.40
Upside: -10.42%
Nov 26, 2024
Maintains: Overweight
Price Target: $165 → $160
Current: $121.63
Upside: +31.55%
Sep 20, 2024
Maintains: Overweight
Price Target: $650 → $670
Current: $499.99
Upside: +34.00%
Aug 7, 2024
Maintains: Underweight
Price Target: $17 → $20
Current: $6.02
Upside: +232.23%
Aug 5, 2024
Maintains: Neutral
Price Target: $1,300 → $1,400
Current: $1,321.45
Upside: +5.94%
Apr 22, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.38
Upside: -
Feb 14, 2024
Upgrades: Overweight
Price Target: $60 → $90
Current: $35.54
Upside: +153.24%
Dec 20, 2023
Maintains: Overweight
Price Target: $250 → $270
Current: $211.80
Upside: +27.48%